Cash, cash equivalents and investments in marketable securities were $132.9M as of December 31, 2025, compared with $167.9M as of June 30, 2025.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- RZLT Earnings this Week: How Will it Perform?
- Rezolute price target raised to $2 from $1 at Wedbush
- Maintaining a Buy on Rezolute: Clear Drug Activity, High-Need Patient Benefit, and Upcoming FDA Catalysts Support Attractive Risk-Reward
- Rezolute (RZLT): Mixed Phase 3 Data, Regulatory Uncertainty in Congenital HI, and Tumor HI Optionality Support Reiterated Hold Rating
- Rezolute: Favorable Risk-Reward on Ersodetug Despite Mixed sunRIZE Data, Supported by Biomarkers, Breakthrough Designation, and Phase 3 Potential